A nonsignificant trend in OS was noted between mBAP1 and WT-BAP1 patients in cohort A (Fig 4 B).
← all excerpts
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
1
—
—
A nonsignificant trend in OS was noted between mBAP1 and WT-BAP1 patients in cohort A (Fig 4 B).